Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi : - ESMO late-breaking data show Libtayo (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC

09/20/2021 | 08:32am EDT

PARIS and TARRYTOWN, N.Y. - Positive Phase 3 results for Sanofi and Regeneron Pharmaceuticals, Inc.'s Libtayo (cemiplimab) combination treatment were presented today during a late-breaking session at the European Society for Medical Oncology Virtual Congress 2021. The trial, which met its primary overall survival (OS) endpoint and all key secondary endpoints, assessed the investigational use of PD-1 inhibitor Libtayo in combination with a physician's choice of platinum-doublet chemotherapy (Libtayo combination) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) irrespective of histology and across all PD-L1 expression levels, compared to chemotherapy alone. These results were also achieved in a patient population with varied baseline characteristics and will form the basis of regulatory submissions, including in the U.S. and European Union (EU).

'Libtayo added to chemotherapy significantly improved patient outcomes, extending median overall survival to 22 months and median progression-free survival to 8 months,' said Miranda Gogishvili, M.D., an oncologist at the High Technology Medical Center University Clinic, in Tbilisi, Georgia and a trial investigator. 'Exploratory analyses showed that survival improvements were seen across squamous and non-squamous histologies and in patients with reduced daily functioning, with 43% of patients having squamous disease and 84% having an ECOG 1 performance status. Furthermore, in another exploratory analysis, the Libtayo combination helped delay deterioration in patient-reported quality of life and pain symptoms.'

In the overall population, patients treated with the Libtayo combination (n=312) experienced significant improvements compared to those receiving chemotherapy alone (n=154), including a: 22-month median OS compared to 13 months for chemotherapy, representing a 29% relative reduction in the risk of death (hazard ratio HR: 0.71; 95% confidence interval CI: 0.53 to 0.93; p=0.014). The 12-month probability of survival was 66% for the Libtayo combination and 56% for chemotherapy.

8-month median progression-free survival (PFS) compared to 5 months for chemotherapy, representing a 46% relative reduction in the risk of disease progression (HR: 0.56; 95% CI: 0.44 to 0.70; p

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
REGENERON PHARMACEUTICALS 0.67% 576.2 Delayed Quote.19.27%
SANOFI 0.49% 85.53 Real-time Quote.8.68%
All news about SANOFI
07:27aREGENERON PHARMACEUTICALS : Second dupixent (dupilumab) phase 3 eosinophilic esophagitis t..
AQ
03:49aSANOFI : Regeneron's Second Late-Stage Inflammatory Disease Trial Meets Primary Endpoints
MT
01:38aSANOFI : Regeneron's Dupixent Improves Swallowing in Late-Stage Study
MT
12:59aSecond Dupixent? Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Dise..
CI
10/22SANOFI : JP Morgan keeps its Buy rating
MD
10/22SANOFI : Regeneron's Dupixent Meets Primary, Key Secondary Endpoints in Phase 3 Trial in P..
MT
10/22REGENERON, SANOFI : Dupixent Hits Main Endpoints in Prurigo Nodularis Trial
DJ
10/22SANOFI : Regeneron's Dupixent Cuts Itch in Late-Stage Skin Disease Study
MT
10/22SANOFI : Dupixent« (dupilumab) is the first biologic to significantly reduce itch and skin..
AQ
10/22Regeneron Pharmaceuticals, Inc. and Sanofi Announces Positive Pivotal Phase 3 Results f..
CI
More news
Analyst Recommendations on SANOFI
More recommendations
Financials
Sales 2021 37 358 M 43 338 M 43 338 M
Net income 2021 6 075 M 7 047 M 7 047 M
Net Debt 2021 8 894 M 10 318 M 10 318 M
P/E ratio 2021 17,8x
Yield 2021 3,86%
Capitalization 107 B 125 B 125 B
EV / Sales 2021 3,11x
EV / Sales 2022 2,84x
Nbr of Employees 99 412
Free-Float 88,4%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 85,53 €
Average target price 105,07 €
Spread / Average Target 22,8%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Chairman
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI8.68%124 266
JOHNSON & JOHNSON4.26%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.17.25%241 985
ELI LILLY AND COMPANY45.14%220 979